| [1] |
Wang L, Zhang H, Ruan Y , et al. Tuberculosis prevalence in China, 1990—2010; a longitudinal analysis of national survey data. Lancet, 2014,383(9934):2057-2064.
doi: 10.1016/S0140-6736(13)62639-2
URL
|
| [2] |
World Health Organization . The WHO end TB strategy. Geneva:World Health Organization, 2015.
|
| [3] |
World Health Organization . Global tuberculosis report 2017. Geneva:World Health Organization, 2017.
|
| [4] |
World Health Organization . Global tuberculosis report 2013. Geneva:World Health Organization, 2013.
|
| [5] |
Pang Y, Zhang Z, Wang Y , et al.Genotyping and prevalence of pyrazinamide- and moxifloxacin-resistant tuberculosis in China2000 to 2010. Antimicrob Agents Chemother , 2017 , 61(2). pii:e02170-16.
|
| [6] |
World Health Organization . Guidelines for establishing DOTs-Plus pilot projects for the management of multidrug-resistant tuberculosis (MDR-TB). Geneva:World Health Organization, 2000.
|
| [7] |
World Health Organization . Guidelines for the programmatic management of drug-resistant tuberculosis. Geneva:World Health Organization, 2006.
|
| [8] |
World Health Organization . Guidelines for the programmatic management of drug-resistant tuberculosis. Geneva:World Health Organization, 2011.
pmid: 21828024
|
| [9] |
World Health Organization . WHO treatment guidelines for drug-resistant tuberculosis. 2016 Update. Geneva: World Health Organization, 2016.
URL
pmid: 27748093
|
| [10] |
Pablos-Méndez A, Raviglione MC, Laszlo A , et al. Global surveillance for antituberculosis-drug resistance, 1994—1997. World Health Organization-International Union against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance. N Engl J Med, 1998,338(23):1641-1649.
doi: 10.1056/NEJM199806043382301
URL
|
| [11] |
Yang C, Shen X, Peng Y , et al. Transmission of Mycobacterium tuberculosis in China: a population-based molecular epidemiologic study. Clin Infect Dis, 2015,61(2):219-227.
doi: 10.1093/cid/civ255
URL
|
| [12] |
World Health Organization . Multidrug and extensively drug-resistant TB (M/XDR-TB): 2010 global report on surveillance and response. Geneva:World Health Organization, 2010.
|
| [13] |
Aung KJ, Van Deun A, Declercq E , et al. Successful '9-month Bangladesh regimen' for multidrug-resistant tuberculosis among over 500 consecutive patients. Int J Tuberc Lung Dis, 2014,18(10):1180-1187.
doi: 10.5588/ijtld.14.0100
URL
|
| [14] |
Kuaban C, Noeske J, Rieder HL , et al. High effectiveness of a 12-month regimen for MDR-TB patients in Cameroon. Int J Tuberc Lung Dis, 2015,19(5):517-524.
doi: 10.5588/ijtld.14.0535
URL
pmid: 25868018
|
| [15] |
Piubello A, Harouna SH, Souleymane MB , et al. High cure rate with standardised short-course multidrug-resistant tuberculosis treatment in Niger: no relapses. Int J Tuberc Lung Dis, 2014,18(10):1188-1194.
doi: 10.5588/ijtld.13.0075
URL
|
| [16] |
Van Deun A, Maug AK, Salim MA , et al. Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am J Respir Crit Care Med, 2010,182(5):684-692.
doi: 10.1164/rccm.201001-0077OC
URL
|
| [17] |
Javaid A, Ahmad N, Khan AH , et al. Applicability of the World Health Organization recommended new shorter regimen in a multidrug-resistant tuberculosis high burden country. Eur Respir J, 2017, 49(1). pii: 1601967.
doi: 10.1183/13993003.01967-2016
URL
|
| [18] |
World Health Organization . The shorter MDR-TB regimen. Geneva: World Health Organization, 2016.
|
| [19] |
Zhang L, Meng Q, Chen S , et al. Treatment outcomes of multidrug-resistant tuberculosis patients in Zhejiang, China,2009—2013. Clin Microbiol Infect, 2017, pii: S1198-743X(17)30363-4. In press.
doi: 10.1016/j.cmi.2017.07.008
URL
pmid: 28712668
|
| [20] |
Zhao Y, Xu S, Wang L , et al. National survey of drug-resis-tant tuberculosis in China. N Engl J Med, 2012,366(23):2161-2170.
doi: 10.1056/NEJMoa1108789
URL
|
| [21] |
Zhang S, Chen J, Shi W , et al. Mutations in panD encoding aspartate decarboxylase are associated with pyrazinamide resistance in Mycobacterium tuberculosis. Emerg Microbes Infect, 2013,2(6):e34.
doi: 10.1038/emi.2013.38
URL
|
| [22] |
Xia Q, Zhao LL, Li F , et al. Phenotypic and genotypic chara-cterization of pyrazinamide resistance among multidrug-resis-tant Mycobacterium tuberculosis isolates in Zhejiang, China. Antimicrob Agents Chemother, 2015,59(3):1690-1695.
doi: 10.1128/AAC.04541-14
URL
|
| [23] |
Tang S, Yao L, Hao X , et al. Clofazimine for the treatment of multidrug-resistant tuberculosis: prospective, multicenter, randomized controlled study in China. Clin Infect Dis, 2015,60(9):1361-1367.
|
| [24] |
Xu HB, Jiang RH, Xiao HP . Clofazimine in the treatment of multidrug-resistant tuberculosis. Clin Microbiol Infect, 2012,18(11):1104-1110.
doi: 10.1111/j.1469-0691.2011.03716.x
URL
pmid: 22192631
|
| [25] |
Dheda K, Gumbo T, Maartens G, , et al. The epidemiology, pathogenesis, transmission,diagnosis, management of multidrug-resistant,extensively drug-resistant incurable tuberculosis. Lancet Respir Med, 2017, pii: S2213-2600(17)30079-6. In press.
|
京公网安备11010202007215号
Total visitors: Visitors of today: Now online:
This work is licensed under Creative Commons Attribution 3.0 License.
